We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Low-Dose CT Monitoring of Lung Nodules Could Spare Unnecessary Surgery

By MedImaging International staff writers
Posted on 04 Sep 2015
Print article
Image: CT images show invasive adenocarcinoma of the lung (photo courtesy of RSNA).
Image: CT images show invasive adenocarcinoma of the lung (photo courtesy of RSNA).
A new study shows that non-solid lung nodules can be safely monitored by performing annual low-dose Computed Tomography (CT) screening.

Non-solid nodules often show up on chest CT scans, and may result in additional imaging tests or surgery. Annual low-dose CT screening could spare patients unnecessary interventions and imaging.

The study was performed by researchers at the Icahn School of Medicine at Mount Sinai Hospital (ISMMS; New York, NY, USA) and included 57,496 participants from the International Early Lung Cancer Program (I-ELCAP). The patients received one baseline, and repeat screenings every subsequent year, during which time the researchers evaluated any non-solid nodules found.

The results of the research suggest that non-solid nodules can be safely followed using annual low-dose CT screening, and can help clinicians assess a potential transition to a part-solid nodule.

Study coauthor Claudia I. Henschke, PhD, MD, Icahn School of Medicine, said, "Nonsolid nodules could be due to inflammation, infection or fibrosis, but could also be cancerous or a precursor of cancer. For screening, we have to define which nodules need further workup and how quickly we have to do that workup. The results show that if we see a nonsolid lung nodule of any size, we can tell people to come back in one year for another CT. These findings are important for reducing unnecessary CT scans and possible biopsies or surgery in programs of CT screening for lung cancer."

The study was published online, in the journal Radiology on July 23, 2015.

Related Links:

Icahn School of Medicine


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Mammography System
MAMMOVISTA B.smart
New
Color Doppler Ultrasound System
DRE Crystal 4PX
Gold Member
Radiation QA Tool
Accu-Gold 3

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.